IMA examines the production of mini tablets through direct compression, looking at how a rotary press tablet affects the operative and formulative parameters.
Tablets
Introduction
Mini tablets are multiple unit dosage forms presenting all the advantages of these systems over the single unit dosage forms such as low risk of dose dumping, high degree of dispersion in the GI tract and reproducible bioavailability. Moreover, if they are manufactured by direct compression instead of granulation or extrusion and spheronization, the production is one step and leads to lower costs and higher production yields[1, 2].
Aim of the study
The aim of the study was first to identify the best manufacturing parameters (die feeder speed, turret speed, pre-compression force, range of possible compression forces) to produce mini tablets with technological characteristics according to European Pharmacopoeia (uniformity of mass, crushing strength, friability).
Subsequently the effect of different cellulose type, molecular weight, particle size and quantity at two different compression forces (Table 1) on technological characteristics (crushing strength, friability) and Theophylline release was evaluated.
Supplied by IMA Active
Materials and methods
In this study nine batches of mini tablets (diameter 2 mm, average weight 7 mg) were obtained by direct compression using a rotary tablet press (Prexima 80, IMA, Table 1) equipped with 2 EU-D punches fitting 24 mini-punches.
As a model soluble drug Theophylline was used combined with different cellulose derivates (hydroxypropylmethylcellulose, HPMC or ethylcellulose, Ethocel) having different molecular weights or particle size (HPMC K4M, HPMC K 100M, Ethocel 7 Standard, Ethocel 100 FP).
Results & Discussion
The results showed that using the proper operative conditions it was possible to obtain stable process: this could be reflected in low relative standard deviation even on compression (analysed on upper and lower punch) than on ejection force (Graph 1 and 2).
Supplied by IMA Active
Supplied by IMA Active
The technology characteristic analysis, resumed in Table 2, showed that all the batches complied with the European Pharmacopoeia for the uniformity of mass and only one batch did not comply with the friability.
Supplied by IMA Active
Regarding the effect of formulative parameters on TH release, data reported in graph 3 showed that all the matrix mini tablets produced had modified release compared to pure TH. In fact pure drug completely dissolved within few minutes (t 50% < 1 min, t 90% = 2 min) according to its great water solubility (release profile not reported). Using HPMC 4KM, the results showed that drug release decreased by increasing the compression force while the polymer amount (33 and 65%) had no significant influence.
Replacing HPMC 4KM with a HPMC with a higher molecular weight (K100M) the difference in the release profile was observed only at the highest compression force. The release profiles of all matrix mini tablets containing Ethocel were observed, as expected, being significantly different from those obtained using HPMC, suggesting a different dissolution mechanism. Moreover it was seen that mini tablets prepared using Ethocel at lower molecular weight had slower drug release than mini tablets prepared from higher molecular weight grades.
Supplied by IMA Active
Conclusions
Both cellulose derivates allow the production of matrix mini tablets containing TH by direct compression. Based on the dissolution profiles, it can be concluded that a more constant and controlled release can be achieved using a hydrophilic polymer (HPMC) releasing the drug by swelling rather than a hydrophobic one controlled by drug diffusion.
REFERENCES
[1] C. M. Lopes, J.M. Sousa Lobo, P. Costa, J.F. Pinto. 2006. Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release. Drug. Dev. Ind. Pharm. (32) 95-106.
[2] T. Riis, A. Bauer-Brandl, T. Wagner, H. Kranz. 2007. pH-independent drug release of an extremely poorly soluble weakly acidic drug from muliparticulated extended release formulations. Eur. J. Pharm. Biopharm. (65) 78-84.